CDK9 and osteosarcoma: Similarly, Ma et al. had demonstrated that, of 70 osteosarcoma patient derived samples, 67.1% exhibited high CDK9 expression, which significantly correlated with metastatic disease, non-survival, worse OS (Overall Survival) and DFS (Disease Free Survival) and poor post-neoadjuvant chemotherapy necrosis.